PDT Partners LLC bought a new position in Tyra Biosciences, Inc. (NASDAQ:TYRA – Free Report) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 25,684 shares of the company’s stock, valued at approximately $820,000.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Janus Henderson Group PLC increased its position in Tyra Biosciences by 32.5% in the first quarter. Janus Henderson Group PLC now owns 3,890,589 shares of the company’s stock worth $148,867,000 after buying an additional 955,147 shares in the last quarter. Commodore Capital LP raised its holdings in Tyra Biosciences by 226.3% during the second quarter. Commodore Capital LP now owns 3,100,000 shares of the company’s stock valued at $29,667,000 after acquiring an additional 2,150,000 shares during the period. BlackRock Inc. bought a new stake in Tyra Biosciences during the second quarter valued at about $96,841,000. Farallon Capital Management LLC lifted its position in shares of Tyra Biosciences by 80.7% in the fourth quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company’s stock valued at $54,337,000 after acquiring an additional 923,000 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Tyra Biosciences by 8.5% in the third quarter. Vanguard Group Inc. now owns 1,520,185 shares of the company’s stock worth $21,267,000 after acquiring an additional 118,492 shares during the period. 84.14% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several equities research analysts have weighed in on the company. Bank of America boosted their price objective on Tyra Biosciences from $37.00 to $42.00 and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Friday, July 17th. JonesTrading initiated coverage on shares of Tyra Biosciences in a research report on Wednesday, June 17th. They set a “buy” rating and a $56.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $45.00 price target on shares of Tyra Biosciences in a report on Thursday, May 14th. Finally, Wolfe Research started coverage on shares of Tyra Biosciences in a report on Tuesday, May 19th. They set a “peer perform” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $46.90.
Tyra Biosciences Stock Performance
Shares of Tyra Biosciences stock opened at $26.13 on Friday. The company has a market capitalization of $1.56 billion, a PE ratio of -10.89 and a beta of 0.77. The company has a 50-day simple moving average of $29.58 and a two-hundred day simple moving average of $32.22. Tyra Biosciences, Inc. has a one year low of $11.70 and a one year high of $40.65.
Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). On average, equities analysts predict that Tyra Biosciences, Inc. will post -2.74 earnings per share for the current fiscal year.
About Tyra Biosciences
Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.
The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.
Read More
- Five stocks we like better than Tyra Biosciences
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Want to see what other hedge funds are holding TYRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tyra Biosciences, Inc. (NASDAQ:TYRA – Free Report).
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
